a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
Conditions: Multiple Myeloma; Plasma Cell Leukemia; Extramedullary Plasmacytoma; Loss of Chromosome 17p; t(14;16); t(4;14); T(14;20); 1Q21 Amplification; Complex Karyotype Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Procedure: Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2; Drug: Melphalan Given IV; Drug: Fludarabine Injection; Drug: PI and dexamethasone as maintenance therapy; Drug: PI+IMids+Dexamethason e as Consolidated Chemotherapy Sponsor: Institute of Hematology & Blood Diseases Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chemotherapy | Clinical Trials | Hematology | Hospitals | Leukemia | Myeloma | Plasmacytoma | Research | Stem Cell Therapy | Stem Cells | Transplants